Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary

• Published in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2019, Vol.15, p.9-9
• Main Authors: Jover Cerdá, Vicente, Rodríguez Pacheco, Ramón, Doménech Witek, Joan, Marco de la Calle, Francisco Manuel, de la Sen Fernández, María Luz
• Format: Report
• Language: English
• ISSN: 1710-1484
• DOI: 10.1186/s13223-019-0327-4

BACKGROUNDPolyethylene glycols (PEGs) and their derivatives are non-ionic polymers of ethylene oxide commercially available with numerous synonyms, such as macrogol, oxyethylene polymer, and laureth-9. Although these polymers are usually safe, mild to life-threatening immediate-type hypersensitivity reactions have been reported. Nevertheless, awareness about their allergic potential is minimal due to the non-standardization of their nomenclature. CASE PRESENTATIONWe present the case of a 29-years-old woman who developed several local and systemic type I hypersensitivity reactions including a severe anaphylactic reaction to different pharmacologic and cosmetic products whose excipients included PEG. Prick tests and basophil activation tests were performed to several pharmacological and cosmetic products, but only those containing PEGs and their derivatives were positive. The patient was diagnosed with immediate hypersensitivity IgE-mediated to PEGs and its derivatives. CONCLUSIONSStandardization of the terminology used to describe the presence of PEGs in products would help patients to identify them clearly and unequivocally and thus avoid the development of hypersensitivity reactions. It is also recommended studying PEG allergy in reactions to products containing PEGs, once allergy to the active ingredients has been excluded and in reactions to multiple unrelated drugs.Clinical study protocol number PI2018/29 (registered on 24 September 2018).